 |
 |
 |
 |
 |
Home » ... » - Faculty » Faculty Pages » Jarrard, David F. |
 |
 |
|
 |
|
 |
 |
|
|
|
Jarrard, David F.
 David F. Jarrard, MD
Associate Professor
Research Area: Prostate Cancer. Oxidative Stress. Insulin-Like Growth Factor II. DNA methylation in cancer development Molecular genetics of prostate cancer.
Home Dept: Department of Urology, School of Medicine and Public Health
Affiliated Depts: Molecular and Environmental Toxicology; Comprehensive Cancer Center
Address
G5/347 Clinical Sciences Center
600 Highland Avenue
Madison, WI 53792-3236
Phone - 608/263-9534 - Email
Research
Dr. Jarrard has a joint appointment with the University of Wisconsin Comprehensive Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He is a pioneer in the use of robotic-assisted prostatectomy.
His laboratory’s basic research is focused on two areas:
1. the role of epigenetics in aging and prostate cancer susceptibility, and
2. the molecular pathways involved in the bypass of senescence.
Many environmental aspects, such as oxidative stress, diet, and hormonal influences, may affect epigenetic marks at imprinted loci. We are currently investigating alterations in imprinting in both an in vitro human prostate epithelial cell model and in vivo in a mouse model of aging. Based on our observation that the peripheral zone of the prostate from men with prostate cancer commonly contains biallelic IGF2 expression, we hypothesize that a loss of imprinting in IGF2, an oncogenic growth factor, contributes to the development of prostate cancer with aging. DNA methylation is a putative regulatory mechanism underlying these alterations in imprinting. Our laboratory has also characterized a number of the genetic events and pathways that occur in human prostate epithelial cells that have overcome or bypassed senescence. These pathways are being examined in human prostate cancer samples for their use as prognostic markers and therapeutic targets.
Publications
- Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol. 2007 Mar;177(3):822-31. Review.
- Best S, Sawers Y, Fu VX, Almassi N, Huang W, Jarrard DF. Integrity of prostatic tissue for molecular analysis after robotic-assisted laparoscopic and open prostatectomy. Urology. 2007 Aug;70(2):328-32.
- Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther. 2006 May;5(5):1335-41.
- Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27.
- Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia. 2005 Sep;7(9):816-23.
- Wilkin M, Horwitz G, Seetharam A, Hartenbach E, Schink JC, Bruskewitz R, Jarrard DF. Long-term complications associated with the Indiana pouch urinary diversion in patients with recurrent gynecologic cancers after high-dose radiation. Urol Oncol. 2005 Jan-Feb;23(1):12-5.
- Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, Jarrard DF. p16 Is upregulated in proliferative inflammatory atrophy of the prostate.
Prostate. 2005 Sep 15;65(1):73-82. - Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate. 2005 Jun 15;64(1):67-74.
- Jarrard DF. Does zinc supplementation increase the risk of prostate cancer? Arch Ophthalmol. 2005 Jan;123(1):102-3.
Check PubMed for other publications by David F. Jarrard
|
|
